Indomethacin

Evidence Level: L5 Predicted Indications: 10

Table of Contents

  1. Indomethacin
    1. Pharmacist Assessment Report
    2. Indomethacin: From Inflammatory Arthritis to Brachydactyly-Syndactyly Syndrome
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. Canada Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Indomethacin: From Inflammatory Arthritis to Brachydactyly-Syndactyly Syndrome

One-Sentence Summary

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) originally used for inflammatory joint and soft-tissue conditions such as rheumatoid arthritis, ankylosing spondylitis, gout and bursitis, and for closing patent ductus arteriosus. The TxGNN model predicts it may be effective for brachydactyly-syndactyly syndrome, a rare congenital limb malformation. No clinical trials and no publications currently support this prediction, so it rests on the model score alone.

Quick Overview

Item Content
Original Indication Inflammatory arthritis and related musculoskeletal conditions (bursitis, synovitis, tenosynovitis, rheumatoid arthritis, ankylosing spondylitis, gout, osteoarthritis) and patent ductus arteriosus
Predicted New Indication Brachydactyly-syndactyly syndrome
TxGNN Prediction Score 0.9997
Evidence Level L5
Canada Market Status Marketed (marketed DINs: 7 of 7)
Number of DINs 7 (marketed: 7)
Recommended Decision Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Indomethacin is generally understood to be a COX-1/COX-2 inhibitor. It reduces prostaglandin-mediated inflammation and pain, which is why it works in arthritis and other inflammatory joint conditions.

For this prediction, a reasonable mechanistic link could not be identified. Brachydactyly-syndactyly syndrome is a rare congenital skeletal malformation of the fingers and toes. It arises from abnormal limb development, not from ongoing inflammation. COX inhibition is not expected to correct a developmental defect.

The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should be treated as a computational signal only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Seven valid single-ingredient authorizations are on the Canadian market. Dosage form and approved-indication text were not available for them.

DIN Product Name
00337439 TEVA-INDOMETHACIN
00337420 TEVA-INDOMETHACIN
02231799 ODAN-INDOMETHACIN
02461811 MINT-INDOMETHACIN
02461536 MINT-INDOMETHACIN

Two further authorizations (02499223 AURO-INDOMETHACIN, 02231800 ODAN-INDOMETHACIN) are also valid but not listed here.

Safety Considerations

Label-based warnings and contraindications were not available. Please refer to the package insert for safety information.

The following comes from drug-disease contraindication links in the knowledge graph, not from label text:

  • Contraindication-related conditions (knowledge graph):
    • Cardiovascular: hypertension, myocardial infarction, coronary thrombosis, heart disease
    • Gastrointestinal: gastric, duodenal and active peptic ulcer, ulcerative colitis and inflammatory bowel disease, necrotizing enterocolitis, esophageal dyskinesia
    • Kidney and liver: kidney disease, liver disease, gallbladder disease
    • Bleeding and blood: blood coagulation disease, thrombocytopenia, intracerebral hemorrhage, hemoglobinopathy
    • Respiratory: asthma (intrinsic and allergic)
    • Neurological and psychiatric: epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder
    • Other: infectious disease
  • Drug interactions: The interaction screen returned 100 interacting drugs in total. The 20 shown in the compiled data are mostly Moderate, with a few Minor.
    • Moderate: acetylsalicylic acid, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), metformin, glimepiride, chlorpropamide, aprepitant, mesalazine, balsalazide, potassium citrate, potassium bicarbonate, picosulfuric acid, polyethylene glycol with electrolytes
    • Minor: famotidine, ranitidine, cimetidine, linaclotide

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has the highest model score but no clinical, literature or mechanistic support. Indomethacin has no known biological reason to modify a congenital limb malformation, and its known risks (GI, renal, cardiovascular, bleeding) are not justified by evidence of benefit.

To proceed, the following is needed:

  • A plausible biological mechanism linking COX inhibition to the developmental pathology of this syndrome
  • Preclinical or case-level evidence of any benefit
  • Mechanism of action data and label-based warnings and contraindications for the Canadian products
  • Consideration of other candidates from the same prediction list. The most evidence-supported is juvenile idiopathic arthritis (TxGNN score 0.9984, Evidence Level L3, with a double-blind crossover trial against ketoprofen and several reviews). It is recommended as Proceed with Guardrails, but it largely extends existing arthritis use rather than being a new repurposing. Guardrails would be pediatric dosing, GI, renal and bleeding risk, and the availability of safer NSAIDs, DMARDs and biologics.

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.